Diederik Hentenaar

119 Phosphoric acid in surgical peri-implantitis treatment group and 63.3% of the implants (53.8% of the patients) in the test group showed no clinical signs of inflammation (PPD ≤ 4mm without bleeding and/or suppuration on probing) (Table 4). The results from the multilevel analyses regarding the effects of the intervention on BoP, SoP and PPD are shown in Table 5. No significant differences in BoP, SoP and mean PPD were detected between control and test group at 3 months after surgery, neither in the “crude” nor in the “adjusted” analysis. Table 3. Log-transformed mean bacterial anaerobic counts (SD) for the control and test group before (T0) and 3 months after (T3) the surgical treatment (paperpoint samples) N = 47* Total anaerobic bacterial load Log-transformed mean (SD) T0 T3 Difference b (95% CI)** p -value Control 6.69 (1.32) 6.31 (1.30) 0.38 (1.36) -0.26 (-0.84 - 0.33) 0.377 Test 6.53 (1.06) 5.98 (0.94) 0.55 (0.99) *3 samples without bacterial growth and 3 samples without follow-up excluded from analysis; SD, standard deviation; **Linear regression analysis, adjusted for baseline values. Table 4. Descriptive statistics of clinical parameters N = Control Test T0 (n = 22) T3 (n = 20) T0 (n = 31) T3 (n = 30) Plaque % of sites (SD) % of implants (n) 4.5 (12.5) 13.6 (3) 10.0 (18.8) 25.0 (5) 4.0 ( 9.3) 16.1 (5) 2.5 (7.6) 9.7 (3) BoP % of sites (SD) % of implants (n) 86.4 (18.5) 100 (22) 28.8 (35.6) 50 (10) 66.1 (29.3) 96.8 (30) 39.2 (31.3) 76.7 (23) SoP % of sites (SD) % of implants (n) 22.7 (24.3) 54.5 (12) 5.0 (15.4) 10.0 (2) 30.7 (20.1) 80.6 (25) 8.3 (20.1) 20.0 (6) Mean PPD Mean (SD) 5.3 (1.1) 3.5 (1.5) 5.2 (1.1) 4.1 (1.6) PPD ≥ 5 mm % of sites (SD) % of implants (n) 67.1 (26.0) 100 (22) 18.8 (30.2) 35.0 (7) 61.3 (22.2) 100 (31) 28.3 (33.9) 46.7 (14) PPD ≥ 6 mm % of sites (SD) % of implants (n) 50.0 (27.8) 100 (22) 12.5 (26.3) 25.0 (5) 46.8 (26.4) 90.3 (28) 24.2 (33.1) 40.0 (12) PPD ≥ 5 mm + BoP/SoP (same site) % of sites (SD) % of implants (n) % of patients (n) 65.9 (26.2) 100 (22) 100 (14/14) 12.5 (25.0) 25.0 (5) 33.3 (4/12) 54.8 (22.7) 100 (31) 100 (14/14) 20.0 (29.7) 36.7 (11) 46.2 (6/13) PPD ≥ 6 mm + BoP/SoP (same site) % of sites (SD) % of implants (n) % of patients (n) 50.0 (27.8) 100 (22) 100 (14/14) 8.8 (20.3) 20.0 (4) 33.3 (4/12) 41.1 (24.6) 90.3 (28) 100 (14/14) 17.5 (28.7) 33.3 (10) 46.2 (6/13) 5